Business
ValiSeek Clinical Update (VAL401)
ValiSeek Clinical Update (VAL401).
About this update from Valirx Plc
[{"type":"text","content":"\n \nRNS Number : 9423B ValiRx PLC 16 January 2018 \n\n \n \n \nVALIRX PLC\n(\"ValiRx\", the \"Company\" or the \"Group\")\n \nVALISEEK CLINICAL UPDATE (VAL401)\n\"Positive Impact of Patient Quality of Life and Immune Competency \nin VAL401 Phase II Clinical Trial\"\n \nLondon, UK., 16 January 2018: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, is pleased to provide an update on the clinical progress and results of VAL401, the anti-cancer compound developed by ValiSeek, the joint venture between ValiRx and Tangent Reprofiling Limited.\n \nFollowing on from the announcement on 12 December 2017 regarding the overall survival results from the completed Phase II Clinical Trial of VAL401 in Tbilisi, Georgia, in the treatment of late stage non-small cell lung cancer, the Company is pleased to release further positive data on the results from this trial. The data analysed by Ariana, a leading digital health Company focused on developing advanced therapeutic decision support systems, shows that the VAL401 treatment has a measureable improvement on patient quality of Life, in addition to a positive impact on the disease.\n \nThe one page information sheet available on the website has now been updated, and can be viewed at: http://1cqi8a4dpf4p8okqjp35hmi5.wpengine.netdna-cdn.com/wp-content/uploads/2018/01/VS-Jan-2018-one-pager.pdf\n \n \nDetailed technical reports are currently being prepared for submission to the regulatory authorities. Subsequent data release will be in the format of peer-reviewed publications in academic journals to ensure that the data is subject to long-term accessibility and will be available on publicly searchable databases. Clinicaltrials.gov will be updated upon agreement with the regulatory authorities of the Clinical Study Report. \n \nResponse for the treatment has been systematically characterised using Ariana's KEM® (Knowledge Extraction and Management) advanced Artificial intelligence technology to identify provide positive relations between response and pharmacokinetic parameters and between response and pre-treatment with particular chemotherapies. This may be indicative of the potential for combining VAL401 with these particular chemotherapies. \n \nProgression Free Survival\nProgression-free survival (\"PFS...